Investors wait Replimune Group, Inc. (NASDAQ:REPL)’s quarterly earnings on May, 9., according to RTT. 45.83 % negative EPS growth is what analysts predict. $-0.24 EPS was announced for last quarter. REPL hit $13.03 during the last trading session after $2.08 change.Replimune Group, Inc. has volume of 63,087 shares. Since April 16, 2018 REPL has 0.00% and is . REPL underperformed by 4.37% the S&P 500.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.The firm is worth $412.36 million. The firm uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer.Last it reported negative earnings. The Company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

For more Replimune Group, Inc. (NASDAQ:REPL) news published briefly go to: Nasdaq.com, Benzinga.com, Seekingalpha.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019 – Nasdaq” published on April 01, 2019, “41 Stocks Moving In Monday’s Mid-Day Session – Benzinga” on March 25, 2019, “NuVasive and OHR Pharmaceutical among healthcare gainers; Celldex Therapeutics leads the losers – Seeking Alpha” with a publish date: February 11, 2019, “Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update – GlobeNewswire” and the last “Replimune set for $101M IPO – Seeking Alpha” with publication date: July 14, 2018.